Relative efficacy and tolerability of 2.5,5,and10 mg tanezumab for the treatmentof osteoarthritis: A Bayesian networkmeta-analysis of randomized controlled trials based on patient withdrawal.

Abstract

To assess the relative efficacy and tolerability of tanezumab (2.5, 5, and 10 mg) in osteoarthritis (OA) patients. Six randomized controlled trials (RCTs) including 3,813 patients and examining the efficacy and tolerability of tanezumab (2.5, 5, 10mg), naproxen (1,000mg), and placebo, based on the number of withdrawals among osteoarthritis patients, were included in this Bayesian random-effects network meta-analysis, which combined direct and indirect evidence. Tanezumab (5, 2.5, 10 mg) and 1,000 mg naproxen were more efficacious than placebo (odds ratio (OR): 0.34, 95% credible interval (CrI): 0.26-0.43; OR: 0.35, 95% CrI: 0.24-0.48; OR: 0.364, 95% CrI: 0.28-0.45; and OR: 0.44, 95% CrI: 0.32-0.61, respectively). The number of withdrawals due to lack of efficacy were lower in the tanezumab groups than in the naproxen group, and the difference was not significant. Ranking probability based on the cumulative ranking curve (SUCRA) indicated that 5mg tanezumab had the highest probability of being the best treatment based on the number of withdrawals due to lack of efficacy, followed by 2.5mg tanezumab, 10mg tanezumab, 1,000mg naproxen, and placebo. Ranking probability based on SUCRA indicated that 2.5mg tanezumab and placebo had the highest probability of being the most tolerable treatment, followed by 5mg tanezumab, 1,000mg naproxen, and 10mg tanezumab. Tanezumab (5mg) had the highest probability of being the best treatment based on the number of withdrawals due to lack of efficacy among the medications, while 2.5mg tanezumab and placebo had the highest probability of being the most tolerable treatment.